GIC  and  Temasek  have signed a binding agreement to acquire “a significant stake” in Novotech, a biotech specialist clinical research organization (CRO). Existing investor TPG will also reinvest in Novetech through its TPG Asia fund, Novotech announced in a press statement posted on its website. Novotech is a Singapore-based full-service clinical CRO, providing biotech to small to mid-sized pharmaceutical companies with an accelerated path to market. It has a global footprint across the Asia-Pacific region, North America and Europe, and partnerships with more than 5,000 trial sites, Novotech said in a statement.   https://sbr.com.sg/healthcare/news/gic-temasek-acquire-significant-stake-in-biotech-cro-novotech (ICE SINGAPORE)

Fonte notizia: Singapore Business Review, 2 April 2025